Table 1.
Characteristics of the study population (n = 896)
| Patients | |
|---|---|
| Age, yearsa | 53.8±6.3 |
| Male | 760 (84.8) |
| Etiology of liver disease | |
| Hepatitis B | 786 (87.7) |
| Hepatitis C | 49 (5.5) |
| Alcohol | 38 (4.2) |
| Others | 23 (2.6) |
| Child-Pugh classification | |
| Class A | 354 (39.5) |
| Class B | 339 (37.8) |
| Class C | 203 (22.7) |
| MELD scoreb | 11 (8–16) |
| Last AFP before LT, ng/mLb | 10.9 (4.4–53.7) |
| Tumor characteristics on pretransplant imaging | |
| Diameter of the largest viable tumora | 1.6±1.6 |
| Viable tumor,a | 1.4±2.6 |
| PET | n = 781 |
| Positivity | 216 (27.7) |
| Types of LT | |
| DDLT | 67 (7.5) |
| LDLT | 829 (92.5) |
| Primary LT (treatment-naïve HCC) | 208 (23.2) |
| LT after treatment | n = 688 |
| Types of treatment | |
| cTACE alone | 409 (59.4) |
| RFA alone | 50 (7.3) |
| Resection alone | 13 (1.9) |
| Radiation alone | 5 (0.7) |
| Combination | 211 (30.7) |
| Radiologic complete response after treatment | 323 (46.9) |
| Tumor characteristics on pathology | n = 706 |
| Edmondson grade | |
| I or II | 293 (41.5) |
| III or IV | 413 (58.5) |
| MVI | 111 (15.7) |
| Satellite nodule | 67 (9.5) |
| Interval from initial HCC diagnosis to LT, monthsb | 9 (3–28) |
Unless otherwise indicated, data represent number of patients with percentage in parentheses. MELD, Model for End-Stage Liver Disease; AFP, alpha-fetoprotein; LT, liver transplantation; PET, positron emission tomography; DDLT, deceased donor liver transplantation; LDLT, living donor liver transplantation; HCC, hepatocellular carcinoma; cTACE, conventional transarterial chemoembolization; RFA, radiofrequency ablation; MVI, microvascular invasion.
a
Data are mean±standard deviation.
b
Data are median with interquartile ranges in parentheses.